Prelude Therapeutics has announced the pricing of a public offering of common stock and pre-funded warrants. The move is expected to raise approximately $90 million in gross proceeds.
- Common stock priced at $4.44 per share
- Over 18 million shares offered
- Pre-funded warrants for 2.25 million shares at $4.4399
- Total gross proceeds estimated at $90 million
- Capital raise intended to support corporate operations
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.